Stocks of Esperion Therapeutics Inc. (NASDAQ:ESPR) traded higher last session on Wall Street, up 10.07% to $1.53.
According to the data, Esperion Therapeutics Inc. (NASDAQ:ESPR) has 9 analysts covering its stock. The consensus rating among analysts is ‘Overweight’. As we calculate the median target price by taking the range between a high of $22.00 and a low of $1.00, we find $10.00. Given the previous closing price of $1.39, this indicates a potential upside of 619.42 percent. ESPR stock price is now 4.75% away from the 50-day moving average and -63.96% away from the 200-day moving average. The market capitalization of the company currently stands at $131.70M.
Top 5 Artificial Intelligence Stocks to Buy for 2024
By now, you're well aware of the artificial intelligence boom. You know Big Tech has been investing billions of dollars into it.
According to Next Move Strategy Consulting, the AI market – currently valued at about $100 billion – cold grow twenty-fold by 2030 to more than $2 trillion. That means you may want to strongly consider these top AI stocks. Get our free report, "Top 5 AI Stocks to Buy in 2024."
Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In"
Sponsored
A total of 1 analysts have issued a hold rating and 7 have given it a buy rating. Brokers who have rated the stock have averaged $10.50 as their price target over the next twelve months.
With the price target enhanced from $1.25 to $4, BofA Securities Upgraded its rating from Underperform to Buy for Esperion Therapeutics Inc. (NASDAQ: ESPR).
In other news, Warren Eric, Chief Commercial Officer sold 106 shares of the company’s stock on Jul 19. The stock was sold for $168 at an average price of $1.58. Upon completion of the transaction, the Chief Commercial Officer now directly owns 69,303 shares in the company, valued at $0.11 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Jun 21, Chief Commercial Officer Warren Eric sold 603 shares of the business’s stock. A total of $894 was realized by selling the stock at an average price of $1.48. This leaves the insider owning 69,409 shares of the company worth $0.11 million. Insiders disposed of 41,348 shares of company stock worth roughly $63262.44 over the past 1 year. A total of 0.60% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in ESPR stock. A new stake in Esperion Therapeutics Inc. shares was purchased by ARMISTICE CAPITAL, LLC during the first quarter worth $5,629,000. TANG CAPITAL MANAGEMENT LLC invested $2,831,000 in shares of ESPR during the first quarter. In the first quarter, NORGES BANK acquired a new stake in Esperion Therapeutics Inc. valued at approximately $1,126,000. XTX TOPCO LTD acquired a new stake in ESPR for approximately $474,000. DAVIDSON KEMPNER CAPITAL MANAGEMENT LP purchased a new stake in ESPR valued at around $340,000 in the second quarter. In total, there are 225 active investors with 87.80% ownership of the company’s stock.
Friday’s opening bell rang with an opening price of $1.4200 for Esperion Therapeutics Inc. (NASDAQ: ESPR). During the past 12 months, Esperion Therapeutics Inc. has had a low of $1.12 and a high of $8.87. The fifty day moving average price for ESPR is $1.4574 and a two-hundred day moving average price translates $4.2151 for the stock.
The latest earnings results from Esperion Therapeutics Inc. (NASDAQ: ESPR) was released for Mar, 2023. According to the Drug Manufacturers – Specialty & Generic Company, earnings per share came in at -$0.79, missing analysts’ expectations of -$0.65 by -0.14. This compares to -$0.93 EPS in the same period last year. The company reported revenue of $24.33 million for the quarter, compared to $18.84 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 29.16 percent. For the current quarter, analysts expect ESPR to generate $24.64M in revenue.
Esperion Therapeutics Inc.(ESPR) Company Profile
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. The company has a license and collaboration agreement with Daiichi Sankyo Europe GmbH; and Serometrix to in-license its oral, small molecule PCSK9 inhibitor program. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.
